Viridian’s Lumvoa becomes first to treat active and chronic thyroid eye disease with single label

Edited by Robert McTiernan··3 min read

Massachusetts-based Viridian Therapeutics (Nasdaq: VRDN) has received US FDA approval for Lumvoa (veligrotug-vvze), a full insulin-like growth factor-1 receptor (IGF-1R) antagonist for the treatment of thyroid eye disease (TED) regardless of disease activity or duration — the first approved therapy to carry labeling encompassing both active and chronic TED, and the first to demonstrate statistically significant effects on both diplopia response and complete diplopia resolution across both disease states.

Lumvoa is administered as five intravenous infusions over 12 weeks, each given every three weeks. The label carries warnings for infusion reactions, inflammatory bowel disease exacerbation, hyperglycemia, and hearing impairment — a safety profile consistent with the IGF-1R antibody class. The approval was granted under Priority Review, and the drug previously received Breakthrough Therapy Designation.

The approval was supported by two pivotal Phase III trials, THRIVE (active TED) and THRIVE-2 (chronic TED). Both trials met their primary and all secondary endpoints, demonstrating statistically significant and clinically meaningful improvements at week 15 across key signs and symptoms of TED. Proptosis reductions were observed as early as three weeks, and both trials reported statistically significant effects on diplopia — an outcome not previously achieved across both disease phases by an approved agent.

Veligrotug-vvze functions as a full antagonist at IGF-1R, blocking a signaling pathway implicated in orbital fibroblast activation and tissue remodeling that drives proptosis and soft tissue changes in TED. Unlike partial inhibitors or antibodies with mixed agonist-antagonist profiles, full receptor blockade is intended to suppress downstream inflammatory signaling more completely, though direct comparative mechanistic data with other approved agents have not been published.

The AllSci BriefSystematic R&D and deal news. Daily.

The TED treatment landscape has shifted substantially since Amgen’s teprotumumab (Tepezza) became the first approved therapy for the condition in 2020. Tepezza, also an IGF-1R monoclonal antibody administered by IV infusion, shares the same broad indication language — approved regardless of TED activity or duration — and represents the incumbent standard of care. Amgen has reported positive Phase III data for a subcutaneous formulation of Tepezza, which, if approved, would further entrench IGF-1R inhibition as the dominant mechanistic approach while potentially improving patient convenience. Beyond the approved class, China-based Innovent Biologics has advanced IBI3031, a bispecific antibody targeting both IGF-1R and the thyroid-stimulating hormone receptor (TSHR), into Phase I, representing a next-generation approach to the same biology. Ethyreal Bio has also raised USD 101 million to develop a TSHR-targeted therapy for Graves’ disease and TED, illustrating continued investor appetite for the space.

For Viridian, Lumvoa is the company’s first commercial product and positions it as a direct competitor to Amgen in a rare disease indication with an established, high-value treatment precedent. The company is also advancing elegrobart, a subcutaneous IGF-1R antibody incorporating Xencor’s Xtend Fc half-life extension technology, with a biologics license application submission targeted for Q1 2027 — a pipeline sequencing that suggests Viridian intends to compete on both clinical differentiation and administration convenience.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/